The principal novel findings are a significant prolonged overall survival of mice treated with the mTor inhibitor everolimus or after therapy with the VEGFR blocker axitinib, as well as a prolonged time to neurological deficit, triggered by a spinal metastatic tumor, in both treatment modalities. This evidence concerns the gene KDR and metastatic neoplasm.